Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Feb 2026
- Primary completion
- Aug 2028
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ponesimod in plaque psoriasis, sponsored by Vanda Pharmaceuticals Inc.. Started Feb 2026; status: recruiting.
02
Drugs
ponesimod
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07362017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362017.